$2.76 Billion is the total value of BVF INC/IL's 83 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 25.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PTGX | Sell | PROTAGONIST THERAPEUTICS INC | $124,890,000 | +80.6% | 3,651,759 | -6.4% | 4.53% | +68.1% |
| ARGX | Sell | ARGENX SEsponsored adr | $75,712,000 | -31.5% | 216,204 | -41.0% | 2.75% | -36.3% |
| SNDX | Sell | SYNDAX PHARMACEUTICALS INC | $45,963,000 | -3.3% | 2,099,714 | -15.6% | 1.67% | -10.0% |
| RVMD | Sell | REVOLUTION MEDICINES INC | $45,572,000 | -33.3% | 1,810,549 | -27.1% | 1.65% | -38.0% |
| SPRO | Sell | SPERO THERAPEUTICS INC | $25,386,000 | -23.8% | 1,585,615 | -12.4% | 0.92% | -29.2% |
| IKNA | Sell | IKENA ONCOLOGY INC | $22,552,000 | -2.5% | 1,798,371 | -1.8% | 0.82% | -9.2% |
| Sell | AADI BIOSCIENCES INC | $21,720,000 | -35.5% | 899,392 | -21.6% | 0.79% | -40.0% | |
| INFI | Sell | INFINITY PHARMACEUTICALS INC | $14,296,000 | -50.1% | 6,353,645 | -24.2% | 0.52% | -53.6% |
| DAWN | Sell | DAY ONE BIOPHARMACEUTICALS I | $13,636,000 | -29.1% | 809,282 | -0.1% | 0.50% | -34.0% |
| ANAB | Exit | ANAPTYSBIO INC | $0 | – | -334,398 | -100.0% | -0.35% | – |
| GRTS | Exit | GRITSTONE BIO INC | $0 | – | -1,528,072 | -100.0% | -0.64% | – |
| Exit | MERUS N V | $0 | – | -5,060,071 | -100.0% | -4.34% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 36 | Q3 2023 | 4.7% |
| PIERIS PHARMACEUTICALS INC | 30 | Q3 2023 | 2.8% |
| CYTOKINETICS INC | 29 | Q4 2020 | 11.8% |
| INFINITY PHARMACEUTICALS INC | 29 | Q2 2023 | 4.3% |
| XOMA CORP DEL | 28 | Q3 2023 | 7.3% |
| ARQULE INC | 27 | Q4 2019 | 4.8% |
| CHEMOCENTRYX INC | 26 | Q3 2019 | 13.8% |
| CYTOMX THERAPEUTICS INC | 26 | Q3 2023 | 5.3% |
| CORVUS PHARMACEUTICALS INC | 26 | Q3 2023 | 2.3% |
| ARRAY BIOPHARMA INC | 25 | Q2 2019 | 14.5% |
View BVF INC/IL's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 4 | 2024-01-29 |
| 3 | 2024-01-26 |
| 4 | 2024-01-09 |
| 4 | 2023-12-20 |
| 4 | 2023-11-17 |
| 13F-HR | 2023-11-14 |
| 3 | 2023-11-13 |
| 3 | 2023-11-06 |
| 4 | 2023-11-06 |
View BVF INC/IL's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.